Skip to content

Chart Industries GTLS Biomedical — Intangible Impairment

Discontinued — last reported Q4 '15

Similar metrics at other companies

IR
IRMedical — Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
$3.7M
Moog Inc. logo
MOG.BIndustrial — Impairment of Intangible Assets, Finite-Lived
$531.25K
Revvity logo
RVTYHuman Health — Intangible Impairment
$50K
DuPont de Nemours, Inc. logo
DDNutrition And Biosciences — Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
$158M
GameStop logo
GMETechnology Brands — Intangible Impairment
$0
IR
IRBiopharma — Impairments
$170.3M

Other financials

Income statement

See full
Revenue$884.8M-11.7%
Gross profit$251.4M-26.0%
Operating income$52.6M-65.5%
Net income-$17.1M-135%
EPS (diluted)-$0.36-138%

Balance sheet

See full
Cash & equivalents$269.4M-9.6%
Total debt$3.9B+1.9%
Total equity$3.2B+5.3%
Total assets$9.7B+4.1%

Cash flow

See full
Operating cash flow-$248.0M-313%
CapEx$24.8M+23.4%
Free cash flow-$272.8M-241%

Valuation

See full
Market cap$9.96B+50.0%
Enterprise value$13.59B+33.6%
P/S2.4×+0.8×

Profitability

See full
Gross margin32.5%-1.3pp
Operating margin6.2%-10.1pp
Net margin-0.6%-6.7pp
FCF margin0.2%-10.3pp

Returns & leverage

See full
Return on equity-0.8%-9.8pp
Debt / equity1.2×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Chart Industries in its filing.

Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsFinitelived.

The official record: Chart Industries’s 10-K, filed February 22, 2018, on SEC EDGAR. View the filing →

Questions, answered.

What does biomedical — intangible impairment mean?
The write-down of the value of finite-lived intangible assets due to reduced expected future utility.
How do you interpret biomedical — intangible impairment?
Higher charges suggest that specific segment assets are losing value faster than originally projected.
How does biomedical — intangible impairment compare across companies?
Similar to 'Amortization and Impairment of Intangibles' reported by peers in the medical technology sector.